Genesis Therapeutics lands $200m Series B

• Other Series B backers include Fidelity Management & Research Company, BlackRock and NVIDIA’s venture capital arm NVentures
• The capital infusion will be used to enable Genesis to evolve into a clinical stage company, further invest in its state-of-the-art AI platform and expand its discovery pipeline
• This funding brings the total capital raised by Genesis Therapeutics to over $280 million

Burlingame, California-based Genesis Therapeutics, an AI-focused developer of medicines for patients with severe diseases, has raised $200 million in Series B funding.

The investors include returning backer Andreessen Horowitz, which led the company’s seed round. Other Series B backers include Fidelity Management & Research Company, BlackRock, and NVIDIA’s venture capital arm NVentures.

The capital infusion will be used will enable Genesis to evolve into a clinical stage company, further invest in its state-of-the-art AI platform, and expand its discovery pipeline.

“AI presents a potent opportunity to revolutionize the drug discovery process, which frequently struggles to produce viable drug candidates against targets that are biologically well-validated but considered undruggable due to highly challenging chemistry,” said Dr. Evan Feinberg, CEO of Genesis, in a statement. “This funding comes as Genesis is approaching an inflection point with the first of our AI-enabled drug candidates entering the clinic.”

This funding brings the total capital raised by Genesis Therapeutics to over $280 million.
.